Anna is a recognized health care strategist and trusted political adviser with more than 25 years of legislative and regulatory experience. Anna assists clients in the health care and life sciences arenas to navigate the process of developing and shaping complex federal legislation and regulatory policy. She works with clients to formulate and implement strategies to achieve their objectives by delivering targeted messages to key decision-makers, building stakeholder coalitions and mobilizing grassroots efforts.
Anna’s knowledge of the intricacies of health policy, combined with her years in the policy-making trenches and her extensive political acumen and relationships on both sides of the aisle, make her uniquely equipped to help clients succeed.
Before starting her own firm, Anna led teams at several top government relations and international law firms where she represented a wide variety of clients in the health care arena focusing on legislative and political issues as well as a wide range of coverage, payment and regulatory policy matters. She was also a lead lobbyist for the Biotechnology Innovation Organization, representing over 1,100 members on health care, intellectual property and biodefense issues. Additionally, she designed and executed federal and state advocacy agendas for a leading U.S. provider of home oxygen and sleep therapy services, equipment and respiratory medications. Anna also directed federal policy and congressional relations on behalf of the major global producers of plasma-based and recombinant biological therapies.
After completing an undergraduate degree at Middlebury College in Vermont, Anna began her career on Capitol Hill working for Senator Patrick Leahy on the Judiciary Committee. Subsequently she was a research assistant at the Harvard School of Public Health and Kennedy School of Government. During graduate school at Georgetown University, she worked in the Executive Office of the President within the Clinton administration, where she served as an aide to the deputy assistant to the president for health policy development.